In a significant development for organ transplantation, two U.S. biotechnology companies, United Therapeutics and ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Scientists from the Cancer Dependency Map (DepMap) at the Broad Institute of MIT and Harvard and Columbia University have ...

RNA-based medicines are one of the most promising ways to fight human disease, as demonstrated by the recent successes of RNA vaccines and double-stranded RNA (dsRNA) therapies. But while health care ...

By treating DNA as a language, Brian Hie’s “ChatGPT for genomes” could pick up patterns that humans can’t see, accelerating ...

In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has ...

An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

Pluristyx, a leading provider of innovative, unmodified, and gene-edited induced pluripotent stem cell (iPSC) lines, submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration ...

Preventing the cell's protein factories from making the notorious cancer-causing protein MYC could stop out-of-control tumors.

A team from UNIGE, the Max Planck Institute for Molecular Physiology in Dortmund, and Heinrich Heine University in Düsseldorf ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...